Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.jcv.2020.104429 http://scihub22266oqcxt.onion/10.1016/j.jcv.2020.104429 32425657!7227587!32425657     free     free     free Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\32425657.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       J+Clin+Virol 2020 ; 128 (ä): 104429 Nephropedia Template TP {{tp|p=32425657|t=2020. Evaluation of the COVID19 ID NOW EUA assay |pdf=|usr=}}{{32425657}} gab.com Text Evaluation of the COVID19 ID NOW EUA assay JO: J Clin Virol http://www.kidney.de/pget.php?&tw=1&pmid=32425657 #FOAvip BACKGROUND: The SARS-CoV-2 pandemic caused a major surge in needed diagnostic capacity. In response, many EUA assays have become available for clinical laboratories, and more recently, the point of care device, Abbott ID NOW. OBJECTIVES: To determine the analytical performance of the ID NOW assay for detecting SARS-CoV-2. STUDY DESIGN: Residual NP samples collected in viral transport media were tested by the ID NOW platform in two independent laboratories. Results were compared to either the CDC or New York EUA assays, which served as reference methods. RESULTS: Overall agreement of ID NOW was 78.7%. Sensitivity was 71.7% and specificity was 100%. Notably, all false-negative results correlated to those samples that were weakly positive. CONCLUSIONS: ID NOW performs well for strong and moderately positive samples but has reduced sensitivity for weakly positive samples. This sensitivity, among other concerns, should be taken into consideration when using this test for patients with a low suspicion for COVID-19 disease. Twit Text FOAVip Evaluation of the COVID19 ID NOW EUA assay ????J Clin Virol http://www.kidney.de/pget.php?&tw=1&pmid=32425657 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32425657 #FOAvip English Wikipedia <ref>{{Cite pmid|32425657}}</ref> Evaluation of the COVID19 ID NOW EUA assay #MMPMID32425657 Mitchell SL; George KS J Clin Virol 2020[Jul]; 128 (ä): 104429 PMID32425657show ga BACKGROUND: The SARS-CoV-2 pandemic caused a major surge in needed diagnostic capacity. In response, many EUA assays have become available for clinical laboratories, and more recently, the point of care device, Abbott ID NOW. OBJECTIVES: To determine the analytical performance of the ID NOW assay for detecting SARS-CoV-2. STUDY DESIGN: Residual NP samples collected in viral transport media were tested by the ID NOW platform in two independent laboratories. Results were compared to either the CDC or New York EUA assays, which served as reference methods. RESULTS: Overall agreement of ID NOW was 78.7%. Sensitivity was 71.7% and specificity was 100%. Notably, all false-negative results correlated to those samples that were weakly positive. CONCLUSIONS: ID NOW performs well for strong and moderately positive samples but has reduced sensitivity for weakly positive samples. This sensitivity, among other concerns, should be taken into consideration when using this test for patients with a low suspicion for COVID-19 disease. |*Pandemics[MESH] |*Point-of-Care Testing[MESH] |Betacoronavirus/*isolation & purification[MESH] |COVID-19[MESH] |COVID-19 Testing[MESH] |Clinical Laboratory Techniques/*methods[MESH] |Coronavirus Infections/*diagnosis[MESH] |False Negative Reactions[MESH] |Humans[MESH] |Pneumonia, Viral/*diagnosis[MESH] |SARS-CoV-2[MESH]Evaluation of the COVID19 ID NOW EUA assay (epmc).pdf DeepDyve Pubget Overpricing